Literature DB >> 17606679

Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis.

Stefan Weiler, Heinz Zoller, Ivo Graziadei, Wolfgang Vogel, Rosa Bellmann-Weiler, Michael Joannidis, Romuald Bellmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17606679      PMCID： PMC2043231          DOI： 10.1128/AAC.00791-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

1.  The safety of voriconazole.

Authors:  Brian A Potoski; Jack Brown
Journal:  Clin Infect Dis       Date:  2002-11-15       Impact factor: 9.079

2.  Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.

Authors:  GholamAli Khoschsorur; Franz Fruehwirth; Sieglinde Zelzer
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.

Authors:  Keith Tan; Nigel Brayshaw; Konrad Tomaszewski; Peter Troke; Nolan Wood
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

4.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors:  Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

5.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

6.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

8.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

Authors:  S J Roffey; S Cole; P Comby; D Gibson; S G Jezequel; A N R Nedderman; D A Smith; D K Walker; N Wood
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

10.  Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.

Authors:  Jan G den Hollander; Cornelis van Arkel; Bart J Rijnders; Pieternella J Lugtenburg; Siem de Marie; Mark-David Levin
Journal:  J Antimicrob Chemother       Date:  2006-03-23       Impact factor: 5.790
  10 in total
  8 in total

Review 1.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

4.  Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease.

Authors:  Stefan Weiler; Elisabeth Überlacher; Julia Schöfmann; Eva Stienecke; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

5.  Update on the optimal use of voriconazole for invasive fungal infections.

Authors:  Asma Lat; George R Thompson
Journal:  Infect Drug Resist       Date:  2011-02-03       Impact factor: 4.003

6.  Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL).

Authors:  Amin T Turki; Jassin Rashidi-Alavijeh; Jan Dürig; Guido Gerken; Peter-Michael Rath; Oliver Witzke
Journal:  BMC Infect Dis       Date:  2017-12-28       Impact factor: 3.090

7.  Voriconazole pharmacokinetics in liver transplant recipients.

Authors:  H J Johnson; Kelong Han; B Capitano; D Blisard; S Husain; P K Linden; A Marcos; E J Kwak; B Potoski; D L Paterson; M Romkes; R Venkataramanan
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

8.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yukihiro Hamada; Issei Tokimatsu; Hiroshige Mikamo; Masao Kimura; Masafumi Seki; Shunji Takakura; Norio Ohmagari; Yoshiko Takahashi; Kei Kasahara; Kazuaki Matsumoto; Kenji Okada; Masahiro Igarashi; Masahiro Kobayashi; Takahiro Mochizuki; Yoshifumi Nishi; Yusuke Tanigawara; Toshimi Kimura; Yoshio Takesue
Journal:  J Infect Chemother       Date:  2013-05-15       Impact factor: 2.211
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.